Temsirolimus in Mantle Cell Lymphoma and Other Non-Hodgkin Lymphoma Subtypes

Seminars in Oncology

Volumn 36, Issue SUPPL. 3, 2009, Pages

  Hess, Georg ^a   Smith, Sonali M ^b   Berkenblit, Anna ^c   Coiffier, Bertrand ^d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

^d CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; CHLORAMBUCIL; CLADRIBINE; CYCLIN D1; CYCLOPHOSPHAMIDE; DEFOROLIMUS; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; GEMCITABINE; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; RITUXIMAB; TEMSIROLIMUS; THALIDOMIDE; VINBLASTINE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; B CELL LYMPHOMA; CANCER RELAPSE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG TOLERABILITY; FATIGUE; FOLLICULAR LYMPHOMA; HUMAN; HYPERGLYCEMIA; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; ONCOGENE; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MODELS, BIOLOGICAL; PROTEIN KINASES; SIROLIMUS;

EID: 72049112821     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.10.012     Document Type: Article

References (45)

1. Witzig T.E. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 23 (2005) 6409-6414
2. Zhou Y., Wang H., Fang W., et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113 (2008) 791-798
3. Gill S., and Ritchie D. Therapeutic options in mantle cell lymphoma. Leuk Lymphoma 49 (2008) 398-409
4. Martin P., Coleman M., and Leonard J.P. Progress in mantle-cell lymphoma. J Clin Oncol 27 (2009) 481-483
5. Herrmann A., Hoster E., Zwingers T., et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27 (2009) 511-518
6. Romaguera J.E., Fayad L., Rodriguez M.A., et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23 (2005) 7013-7023
7. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112 (2008) 2687-2693
8. Martin P., Chadburn A., Christos P., et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 19 (2008) 1327-1330
9. Cohen B.J., Moskowitz C., Straus D., Noy A., Hedrick E., and Zelenetz A. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 42 (2001) 1015-1022
10. Inwards D.J., Fishkin P.A., Hillman D.W., et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 113 (2008) 108-116
11. Wiernik P.H., Lossos I.S., Tuscano J.M., et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 26 (2008) 4952-4957
12. Kaufmann H., Raderer M., Wohrer S., et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104 (2004) 2269-2271
13. Rummel M.J., Al-Batran S.E., Kim S.Z., et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 3383-3389
14. Kane R.C., Dagher R., Farrell A., et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13 (2007) 5291-5294
15. Belch A., Kouroukis C.T., Crump M., et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 18 (2007) 116-121
16. Fisher R.I., Bernstein S.H., Kahl B.S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24 (2006) 4867-4874
17. Witzig T.E., Geyer S.M., Ghobrial I., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23 (2005) 5347-5356
18. Ansell S.M., Inwards D.J., Rowland Jr. K.M., et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 113 (2008) 508-514
19. Hess G., Herbrecht R., Romaguera J., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27 (2009) 3822-3829
20. Coiffier B., and Ribrag V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leuk Lymphoma (2009 Sep 8) [Epub ahead of print]
21. Marzec M., Kasprzycka M., Liu X., et al. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 26 (2007) 5606-5614
22. Leseux L., Hamdi S.M., Al S.T., et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 108 (2006) 4156-4162
23. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4 (2004) 335-348
24. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
25. Bertoni F., Zucca E., and Cotter F.E. Molecular basis of mantle cell lymphoma. Br J Haematol 124 (2004) 130-140
26. Witzig T.E., and Kaufmann S.H. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 7 (2006) 285-294
27. Costa L.J. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev 33 (2007) 78-84
28. Rudelius M., Pittaluga S., Nishizuka S., et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108 (2006) 1668-1676
29. Peponi E., Drakos E., Reyes G., Leventaki V., Rassidakis G.Z., and Medeiros L.J. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 169 (2006) 2171-2180
30. Yazbeck V.Y., Buglio D., Georgakis G.V., et al. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 36 (2008) 443-450
31. Haritunians T., Mori A., O'Kelly J., Luong Q.T., Giles F.J., and Koeffler H.P. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21 (2007) 333-339
32. Yee K.W., Zeng Z., Konopleva M., et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12 (2006) 5165-5173
33. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 (1999) 1244-1253
34. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
35. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
36. Reeder C.B., Gornet M.K., and Habermann T.M. A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL) [abstract 121]. Blood 110 (2007) 44a
37. Wendel H.G., De S.E., Fridman J.S., et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
38. Wlodarski P., Kasprzycka M., Liu X., et al. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 65 (2005) 7800-7808
39. Smith S.M., and van Besien K. mTOR inhibition in lymphoma: a rational and promising strategy. Lett Drug Design Discov 4 (2007) 224-231
40. Smith S.M. Clinical development of mTOR inhibitors: a focus on lymphoma. Rev Recent Clin Trials 2 (2007) 103-110
41. Smith S.M., Pro B., Cisneros A., et al. Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes [abstract 8514]. J Clin Oncol, 2008 ASCO Annual Meeting Proceedings 26 suppl 15S (2008) 457s part I
42. Johnston P.B., Ansell S.M., Colgan J.P., et al. Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma [abstract 8055]. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25 suppl 18S (2007) part I
43. Mita M.M., Mita A.C., Chu Q.S., et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26 (2008) 361-367
44. Rizzieri D.A., Feldman E., Dipersio J.F., et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14 (2008) 2756-2762
45. Decker T., Sandherr M., Goetze K., Oelsner M., Ringshausen I., and Peschel C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol 88 (2008) 221-227